Bradley Foster & Sargent Inc. CT bought a new position in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 56,663 shares of the company's stock, valued at approximately $871,000. Bradley Foster & Sargent Inc. CT owned approximately 0.21% of ClearPoint Neuro at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in shares of ClearPoint Neuro by 1.5% in the 3rd quarter. Geode Capital Management LLC now owns 287,294 shares of the company's stock worth $3,222,000 after purchasing an additional 4,170 shares during the last quarter. Conway Capital Management Inc. lifted its holdings in shares of ClearPoint Neuro by 13.9% in the 4th quarter. Conway Capital Management Inc. now owns 161,225 shares of the company's stock worth $2,480,000 after purchasing an additional 19,725 shares during the last quarter. Parsons Capital Management Inc. RI lifted its holdings in shares of ClearPoint Neuro by 1.9% in the 4th quarter. Parsons Capital Management Inc. RI now owns 141,573 shares of the company's stock worth $2,177,000 after purchasing an additional 2,600 shares during the last quarter. Pekin Hardy Strauss Inc. bought a new stake in shares of ClearPoint Neuro in the 3rd quarter worth approximately $541,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of ClearPoint Neuro in the 3rd quarter worth approximately $366,000. Institutional investors and hedge funds own 30.08% of the company's stock.
ClearPoint Neuro Stock Down 4.2 %
ClearPoint Neuro stock traded down $0.73 during mid-day trading on Friday, hitting $16.72. 191,341 shares of the company's stock traded hands, compared to its average volume of 169,775. ClearPoint Neuro, Inc. has a one year low of $5.11 and a one year high of $19.22. The firm has a 50 day moving average price of $16.61 and a 200 day moving average price of $13.62. The company has a market cap of $461.14 million, a PE ratio of -24.23 and a beta of 1.03.
Wall Street Analyst Weigh In
Several analysts recently issued reports on CLPT shares. B. Riley raised their price target on ClearPoint Neuro from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. Lake Street Capital raised their price target on ClearPoint Neuro from $17.00 to $30.00 and gave the stock a "buy" rating in a report on Tuesday, January 21st.
Read Our Latest Stock Analysis on ClearPoint Neuro
ClearPoint Neuro Company Profile
(
Free Report)
ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.
Read More
Before you consider ClearPoint Neuro, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ClearPoint Neuro wasn't on the list.
While ClearPoint Neuro currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
